Aurinia Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 323.07, 383.96, 452.42, 470.84, 515.74 ], "ebit_estimate": [ 154.29, 190.05, 192.5, 265.46, 310.79 ], "ebitda_estimate": [ 159.7, 192, 215.43, 257.53, null ], "net_income_estimate": [ 129.44, 161.49, 206.44, 207.24, 241.94 ], "per_share_eps_estimate": [ 1.02, 1.22, 1.52, 1.43, 1.46 ], "eps_nri_estimate": [ 0.96, 1.24, 1.8, 1.56, 1.92 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ 164.55, 203.16, 261.52, 275.72, 321.06 ], "operating_cash_flow_per_share_estimate": [ 1.24, 1.81, 1.64, 1.73, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null ], "gross_margin_estimate": [ 91, 92, 92, 92, 92 ], "operating_cash_flow_estimate": [ 170.67, 249.13, 225.73, 238.12, null ], "pettm_estimate": [ 15.51, 12.99, 10.39, 11.02, 10.82 ], "long_term_growth_rate_mean": 30.32, "long_term_revenue_growth_rate_mean": "17.11", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": 30.32, "future_revenue_estimate_growth": 17.11, "future_ebit_estimate_growth": 22.5, "future_ebitda_estimate_growth": 20.11, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 22.79, "future_pretax_income_estimate_growth": 30.97, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 1.28, "future_operating_cash_flow_per_share_estimate_growth": 21.28 }

{ "date": [ "202606", "202609", "202612" ], "revenue_estimate": [ 79.7, 81.43, 85.02 ], "ebit_estimate": [ 40.49, 39.2, 38.99 ], "ebitda_estimate": [ null, null, null ], "net_income_estimate": [ 32.54, 32, 32.25 ], "per_share_eps_estimate": [ 0.25, 0.23, 0.23 ], "eps_nri_estimate": [ 0.24, 0.24, 0.24 ], "dividend_estimate": [ null, null, null ], "book_value_per_share_estimate": [ null, null, null ], "pretax_income_estimate": [ 39.79, 39.33, 40.05 ], "operating_cash_flow_per_share_estimate": [ 0.35, 0.33, 0.32 ], "roa_estimate": [ null, null, null ], "roe_estimate": [ null, null, null ], "gross_margin_estimate": [ 91, 91, 91 ], "operating_cash_flow_estimate": [ 48.17, 45.42, 44.04 ], "pettm_estimate": [ null, null, null ], "long_term_growth_rate_mean": 30.32, "long_term_revenue_growth_rate_mean": "17.11", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": 30.32, "future_revenue_estimate_growth": 17.11, "future_ebit_estimate_growth": 22.5, "future_ebitda_estimate_growth": 20.11, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 22.79, "future_pretax_income_estimate_growth": 30.97, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 1.28, "future_operating_cash_flow_per_share_estimate_growth": 21.28 }